Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates Dynavax Technologies has partnered with the Coalition for Epidemic Preparedness Innovations (CEPI) to create a vaccine against Covid-19 infection.
The company will provide access to its toll-like receptor 9 (TLR9) agonist adjuvant, CpG 101, to enable the development of vaccines.
Previously, CpG 1018 was used in HEPLISAV-B, a US Food and Drug Administration (FDA)-approved hepatitis B vaccine for adults, designed to boost vaccine immune response.
Dynavax CEO Ryan Spencer said: “Dynavax’s mission is to develop and commercialise innovative vaccines to prevent disease and support patients. “We are proud to support CEPI’s efforts to address this global public
Read more on pharmaceutical-technology.com